Why the study?
Do volatile anesthetics prevent ischemic cardiac dysfunction in patients undergoing cardiac surgery?
Do volatile anesthetics prevent ischemic cardiac dysfunction in patients undergoing cardiac surgery?
Volatile anesthetics may provide an additional therapeutic tool for the prevention and treatment of ischemic cardiac dysfunction during the perioperative period of cardiac surgery.
Extends experimental cardioprotection signals to cardiac surgery patients; hypothesis-generating and requires prospective outcome trials before practice change.
Myocardial ischemia during the perioperative period is a major cause of morbidity and mortality after surgery. Experimental data indicate that clinical concentrations of volatile anesthetics protect the myocardium from ischemia and reperfusion injury, as shown by decreased infarct size and more rapid postoperative recovery of contractile function. These anesthetics may also mediate protective effects in other organs, such as the brain and kidney. A number of recent reports have indicated that these experimentally observed protective effects might also be present in the clinical setting. Implementation of such cardioprotection during surgery may provide an additional tool in the treatment and prevention of ischemic cardiac dysfunction in the perioperative period. This review discusses the clinical studies that have focused on the potential cardioprotective effects of volatile anesthetic agents.
No takes yet. Share an insight, caveat, or question.
Lorsomradee et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: